Pulmonary inhalation aerosols for targeted antibiotics drug delivery

European Pharmaceutical Review

Volumn , Issue 1, 2011, Pages

  Park, Chun Woong ^a   Mansour, Heidi M ^{a,g,h,i,j,k,l}   Hayes Jr , Don ^b,c,d,e,f  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^d American Thoracic Society   (United States)

^e American College of Chest Physicians   (United States)

^f International Society for Heart and Lung Transplantation   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ UNIVERSITY OF KENTUCKY   (United States)

^j American Association of Pharmaceutical Scientists AAPS   (United States)

^k College of Engineering ^*  (United Kingdom)

^l European Cystic Fibrosis Society (ECFS)   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETONE; ACETYLCYSTEINE; ALCOHOL; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMMONIA; ANTIBIOTIC AGENT; ARIKACE; ASCORBIC ACID; AZITHROMYCIN; AZTREONAM; AZTREONAM LYSINE; BAY 416551; BAYQ 3939; BENZALKONIUM CHLORIDE; CAPREOMYCIN; CETYLPYRIDINIUM SALT; CHLORBUTOL; CIPROFLOXACIN; CITRIC ACID; COLISTIN; CRYOFLUORANE; DICHLORODIFLUOROMETHANE; EDETATE DISODIUM; GLYCOPEPTIDE; LEVOFLOXACIN; MACROLIDE; MONOBACTAM DERIVATIVE; MOXIFLOXACIN; MP 376; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

AEROSOL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; REVIEW;

EID: 79954994721     PISSN: 13608606     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (49)

1. Smaldone GC and Palmer LB. (2000) Aerosolized Antibiotics: Current and Future. Respiratory Care, 45:667-675 (Pubitemid 30484806)
2. Flume P and Klepser ME. (2002) The rationale for aerosolized antibiotics. Pharmacotherapy, 22: S71-S79
3. Craig WA. (1997) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12
4. Fitzsimmons SC. (1993) The changing epidemiology of cystic fibrosis. J Pediatr 122:1-9
5. Beringer PM.(1999) New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Curr Opin Pulm Med 5:371-7
6. Moss RB. (2001) Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 120:107-113
7. Sexauer WP and Fiel SB. (2003) Aerosolized antibiotics in cystic fibrosis. Semin Respir Crit Care Med 24:717-726 (Pubitemid 38036766)
8. Gibson RL, Burns JL, Ramsey BW. (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168:918-951 (Pubitemid 37267172)
9. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. (1985) Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 132:761-7
10. Eisenberg J, Pepe M, Williams-Warren J. (1997) A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized tobramycin study group. Chest 111:955-62 (Pubitemid 27171467)
11. Ramsey BW, Burns J, Smith A. (1997) Safety and efficacy of tobramycin solution for inhalation in patients with cystic fibrosis: the results of two phase III placebo controlled clinical trials. Pediatr Pulmonol suppl 14:137-8
12. Novartis pharmaceutical Inc. Tobramycin solution for inhalation (2010) Available from: http://www.tobitime.com
13. Gilead. Aztreonam for inhalation solution (2009) Available from: http://www.gilead.com/pipeline
14. Hickey A.J. and Mansour H.M. (2009) Chapter 5: Delivery of Drugs by the Pulmonary Route. Modern Pharmaceutics Volume 2: Applications and Advances Fifth Edition. Taylor & Francis, Inc., New York. 191-219
15. Beasley R and Hendeles L. (1999) Preservatives in nebulizer solutions: risks without benefit-a further comment. Pharmacotherapy 19:473-4 (Pubitemid 29160165)
16. Beasley R, Burgess C, Holt S. (2001) Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions. J Allergy Clin Immunol 107:222-3 (Pubitemid 32173895)
17. Asmus MJ, Sherman J, Hendeles L. (1999) Bronchoconstrictor additives in bronchodilator solutions. J Allergy Clin Immunol 104:553-60
18. De Boer AH, Winter HMI, Lerk CF. (1996) Inhalation characteristics and their effect on in-vitro drug delivery from dry powder inhalers. Int J Pharm 130:231-244
19. Hickey A.J. and Mansour H.M. (2008) Chapter 44: Formulation Challenges of Powders for the Delivery of Small Molecular Weight Molecules as Aerosols. Modified-Release Drug Delivery Technology Second Edition. Informa Healthcare, New York. 573-602
20. Steckel H and Müller BW. (1997) In vitro evaluation of dry powder inhalers. I. Drug deposition of commonly used devices. Int J Pharm 154:19-29
21. Srichana T, Martin GP, Mariott C. (1998) Dry powder inhalers: The influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci 7:73-80 (Pubitemid 29056229)
22. Inactive ingredient database for approved drug products by FDA. (2010) Available from: http://www.accessdata.fda.gov/scripts/cder/iig/ index.cfm
23. Pilcer G and Amighi K. (2010) Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 392:1-19
24. Clay MM and Clarke SW. (1987) Wastage of drug from nebulisers: a review. J R Soc Med 80:38-39 (Pubitemid 17228091)
25. Newhouse MT, Hirst PH, Duddu SP, et al. (2003) Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 124:360-6 (Pubitemid 36851374)
26. Geller DE, Konstan MW, Konstan MW, et al. (2007) Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulm 42:307-13 (Pubitemid 46608898)
27. Pilcer G, Sebti T, Amighi K. (2006) Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res 23:931-40 (Pubitemid 43781401)
28. Pilcer G, Goole J, Van Gansbeke B, et al. (2008) Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. Eur J Pharm Biopharm 68:413-21
29. Parlati C, Buttini F, Ammit AJ, et al. (2009) Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. Pharm Res 26:1084-92
30. Garcia-Contreras L, Fiegel J, Telko MJ, et al. (2007) Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 51: 2830-6 (Pubitemid 47206218)
31. Nektar. Anti-Infectives. (2009) Available from: http://www.nektar.com/ product-pipeline/all-phases.html
32. Shah SP, Misra A. (2004) Liposomal Amikacin Dry Powder Inhaler: Effect of Fines on In Vitro Performance. AAPS PharmSciTech 5: E65
33. Omri A, Beaulac C, Lagacé J, et al. (1994) Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 38:1090-5 (Pubitemid 24150843)
34. Mugabe C, Azghani AO, Omri A. (2005) Liposomemediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 55: 269-71 (Pubitemid 40331158)
35. Adi H, Young PM, Chan HK, et al. (2008) Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci 97:3356-66
36. Adi H, Young PM, Chan HK, et al. (2010) Controlled release antibiotics for dry powder lung delivery. Drug Dev Ind Pharm 36:119-126
37. Tsifansky MD, Yeo Y, Evgenov OV, et al. (2008) Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J 10:254-60
38. Zhao H, Liu H, Hu T, et al. (2009) Preparation of microsized spherical aggregates of ultrafine ciprofloxacin particles for dry powder inhalation (DPI). Powder Technol 194:81-6
39. Sweeney L, Wang Z, Finlay W, et al. (2005) Spray-freezedried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 305:180-5 (Pubitemid 41568373)
40. Waldrep JC and Dhand R. (2008) Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv 5:114-9 (Pubitemid 351536317)
41. Prescott WA and Johnson CE. (2005) Antiinflammatory therapies for cystic fibrosis: past, present, and future. Pharmacotherapy 25:555-73
42. Hickey AJ, Lu D, Ashley ED, et al. (2006) Inhaled azithromycin therapy. J Aerosol Med. 19:54-60
43. Zhao M, Yao Y, Ren Y, et al. (2008) Formulation, characteristics and aerosolization performance of azithromycin DPI prepared by spray-drying. Powder Technol 187:214-21
44. De Boer AH, Le Brun PPH, van der Woude HG, et al. (2002) Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur J Pharm Biopharm 54:17-24 (Pubitemid 34663852)
45. Le Brun PPH, de Boer AH, Mannes GPM, et al. (2002) Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2 Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 54:25-32 (Pubitemid 34663853)
46. Search for clinical trials. 2010. available from: http://www. clinicaltrial.gov/ct2/search
47. Misra A, Jinturkar K, Patel D, et al. (2009) Recent advances in liposomal dry powder formulations: preparation and evaluation. Expert Opin Drug Deliv 6:71-89
48. Traini D and Young PM. (2009) Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv 6: 897-905
49. Kuhn RJ. (2001) Formulation of aerosolized therapeutics. Chest 120:94S-98S